anti cd45 ptprc antibody  (Boster Bio)

Journal: iScience

Article Title: Immune hub genes and a proof-of-concept prognostic signature in EBV-associated gastric carcinoma

doi: 10.1016/j.isci.2026.115243

Figure Lengend Snippet: Expression and immune correlation of hub genes (A) Violin plots show the expression levels of PTPRC and ITGB2 in EBVaGC (blue) and EBVnGC (red) from the TCGA-STAD cohort. Statistical significance is indicated (∗ p < 0.05 and ∗∗ p < 0.01). (B) Correlation heatmap illustrates the relationships between hub genes (PTPRC and ITGB2) and 22 tumor-infiltrating immune cell subsets. Circle size and color intensity represent the strength of correlation, with orange indicating positive correlations and teal indicating negative correlations. (C) Scatterplots demonstrates correlations between PTPRC expression and infiltration levels of five immune cell types: B cells memory, CD4 + memory activated T cells, CD8 + T cells, M1 macrophages, and M2 macrophages. Pearson’s correlation coefficients (R) and p values are shown for each comparison. (D) Scatterplots show correlations between ITGB2 expression and infiltration levels of the same five immune cell types as in (C). Pearson’s correlation coefficients (R) and p values are indicated.

Article Snippet: Anti-CD45 (PTPRC), mouse monoclonal, clone PD7/26+2B11 , Zhongshan Golden Bridge Biotechnology (ZSGB-BIO) , Cat# Kit-0024.

Techniques: Expressing, Comparison

Journal: iScience

Article Title: Immune hub genes and a proof-of-concept prognostic signature in EBV-associated gastric carcinoma

doi: 10.1016/j.isci.2026.115243

Figure Lengend Snippet: Increased CD18+, CD45+, and CD68 + immune-cell infiltration in EBVaGC (A) Representative immunohistochemistry (IHC) micrographs for CD18, CD45, and CD68 in EBVaGC (top) and EBVnGC (bottom). Brown DAB indicates positive staining; hematoxylin counterstain. Images were acquired at 40× objective; scale bars, 50 μm. (B) Dot-and-box plots showing quantitative cell densities (cells/mm 2 ) of CD18 + , CD45 + , and CD68 + cells in EBVaGC versus EBVnGC. Each dot represents one case (EBVaGC n = 20; EBVnGC n = 20; per case, the mean of ≥3 non-necrotic high-power fields was used). Boxes show IQR, center line the median, whiskers the range. p values are from two-sided exact Wilcoxon rank-sum tests (CD18: ∗∗∗ p < 0.0001; CD45: ∗∗∗ p < 0.0001; and CD68: ∗∗∗ p < 0.0001). Units and statistics are indicated on the plots.

Article Snippet: Anti-CD45 (PTPRC), mouse monoclonal, clone PD7/26+2B11 , Zhongshan Golden Bridge Biotechnology (ZSGB-BIO) , Cat# Kit-0024.

Techniques: Immunohistochemistry, Staining

Journal: iScience

Article Title: Immune hub genes and a proof-of-concept prognostic signature in EBV-associated gastric carcinoma

doi: 10.1016/j.isci.2026.115243

Figure Lengend Snippet: Construction and characterization of the four-gene immune score model in EBVaGC (A) Co-expression analysis of PTPRC and ITGB2 in EBVaGC samples. High-high expression pairs are highlighted in red. (B) GO biological process enrichment of immune genes co-expressed with PTPRC and ITGB2, highlighting terms such as leukocyte-mediated immunity and T cell activation. (C) KEGG pathway enrichment showing cytokine-cytokine receptor interaction, chemokine signaling, and other immune-related pathways. (D) LASSO Cox regression coefficients (lambda.min) for the selected prognostic genes GMPR and TIMD4. (E) Heatmap of GMPR and TIMD4 expression across risk groups. (F) Forest plot of multivariate Cox regression showing hazard ratios (HRs) and 95% confidence intervals for the four model genes. (G) GO enrichment of the final model genes, revealing involvement in phagocytosis, glial cell activation, and inflammatory response. (H) KEGG enrichment of model genes, with pathways such as cell adhesion molecules and primary immunodeficiency.

Article Snippet: Anti-CD45 (PTPRC), mouse monoclonal, clone PD7/26+2B11 , Zhongshan Golden Bridge Biotechnology (ZSGB-BIO) , Cat# Kit-0024.

Techniques: Expressing, Activation Assay

Journal: International Journal of Molecular Sciences

Article Title: Cytosine Deaminase-TRAIL Expressing Human Adipose Stem Cells Inhibit Tumor Growth in Castration Resistant Prostate Cancer Bearing Mice with Less Toxicity

doi: 10.3390/ijms27031563

Figure Lengend Snippet: Flow cytometric characterization of parental hTERT-ADSC and ADSC.CD.sTRAIL cells. Representative flow histograms for surface markers. Blue peaks = specific antibody staining; gray peaks = isotype control. Both cell types were strongly positive for MSC markers CD90 and CD105, and negative for hematopoietic markers CD34 and CD45. These results confirm maintenance of the MSC phenotype after immortalization and genetic modification. Abbreviations: ADSC—adipose-derived stem cell.

Article Snippet: Cells were stained with antibodies against canonical MSC surface markers CD29, CD90, and CD105, as well as hematopoietic lineage markers CD34 and CD45 (all antibodies 1:50 dilution; Origene or Invitrogen, Rockville, MD, USA).

Techniques: Staining, Control, Modification, Derivative Assay

Journal: International Journal of Molecular Sciences

Article Title: Integrative Multi-Omics Analysis Reveals Molecular Signatures of Recurrence in Paired Primary and Recurrent High-Grade Serous Ovarian Cancer

doi: 10.3390/ijms27020948

Figure Lengend Snippet: Differential expression and prognostic significance of candidate differentially expressed genes (DEGs) in primary and recurrent high-grade serous ovarian cancer. ( A ) Heatmap showing the expression levels of selected DEGs in primary and recurrent tumor samples. Columns represent individual tumor samples (primary, yellow; recurrent, green), and rows represent DEGs. Color intensity indicates relative expression levels, ranging from blue (low) to red (high). ( B ) Kaplan–Meier curves showing time to recurrence for patients stratified into high- and low-expression groups for each indicated DEG ( GPR68 , IL7R , IRF8 , PTPRC , WDFY4 , C15orf39 , NSG1 ). Statistical significance was evaluated using the log-rank test, with p -values shown on each plot.

Article Snippet: The primary antibodies used were IL7R (Abcam, Cambridge, UK, #ab259806), IRF8 (Cell Signaling, Danvers, MA, USA, #83413), GPR68 (Abcam, #ab61420), PTPRC (Cell Signaling, #13917), WDFY4 (Abcam, #ab122661), and NSG1 (Invitrogen, #PA5-36497).

Techniques: Quantitative Proteomics, Expressing

Journal: International Journal of Molecular Sciences

Article Title: Integrative Multi-Omics Analysis Reveals Molecular Signatures of Recurrence in Paired Primary and Recurrent High-Grade Serous Ovarian Cancer

doi: 10.3390/ijms27020948

Figure Lengend Snippet: Differential protein expression of six candidate genes in matched primary and recurrent high-grade serous ovarian cancer tissues assessed by immunohistochemistry. ( A ) Representative immunohistochemical staining of IL7R, IRF8, GPR68, PTPRC, WDFY4, and NSG1 in tissue microarrays derived from paired primary and recurrent tumor samples. Scale bars represent 50 or 100 µm. Notable differences in expression were observed for IL7R, PTPRC, and NSG1 between matched tumor pairs. ( B ) Paired dot plots showing immunohistochemical staining scores for each of the six proteins. Black lines connect matched tumor pairs (primary and recurrent) from the same patient. Statistical significance of expression differences between primary and recurrent tumor samples was assessed using paired t -tests.

Article Snippet: The primary antibodies used were IL7R (Abcam, Cambridge, UK, #ab259806), IRF8 (Cell Signaling, Danvers, MA, USA, #83413), GPR68 (Abcam, #ab61420), PTPRC (Cell Signaling, #13917), WDFY4 (Abcam, #ab122661), and NSG1 (Invitrogen, #PA5-36497).

Techniques: Expressing, Immunohistochemistry, Immunohistochemical staining, Staining, Derivative Assay